Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain

被引:22
|
作者
Bonomi, Robin [1 ]
Mukhopadhyay, Uday [5 ]
Shavrin, Aleksandr [1 ]
Yeh, Hsien-Hsien [6 ,7 ]
Majhi, Anjoy [1 ]
Dewage, Sajeewa W. [3 ]
Najjar, Amer [4 ]
Lu, Xin [1 ]
Cisneros, G. Andres [3 ]
Tong, William P. [4 ]
Alauddin, Mian M. [4 ]
Liu, Ren-Shuan [6 ,7 ]
Mangner, Thomas J. [2 ]
Turkman, Nashaat [1 ]
Gelovani, Juri G. [1 ]
机构
[1] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48202 USA
[2] Wayne State Univ, Positron Emiss Tomog Ctr, Detroit, MI 48202 USA
[3] Wayne State Univ, Dept Chem, Detroit, MI 48202 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Ctr Adv Biomed Imaging, Houston, TX 77030 USA
[6] Natl Yang Ming Univ, Natl Cyclotron & Radiochem Ctr, Taipei 112, Taiwan
[7] Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci, Taipei 112, Taiwan
来源
PLOS ONE | 2015年 / 10卷 / 08期
关键词
CENTRAL-NERVOUS-SYSTEM; IN-VIVO; CATALYTIC-ACTIVITY; INHIBITION; SPECIFICITY; ROLES; HDACS;
D O I
10.1371/journal.pone.0133512
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Histone deacetylases (HDAC's) became increasingly important targets for therapy of various diseases, resulting in a pressing need to develop HDAC class-and isoform-selective inhibitors. Class IIa deacetylases possess only minimal deacetylase activity against acetylated histones, but have several other client proteins as substrates through which they participate in epigenetic regulation. Herein, we report the radiosyntheses of the second generation of HDAC class IIa-specific radiotracers: 6-(di-fluoroacetamido)-1-hexanoicanilide (DFAHA) and 6-(tri-fluoroacetamido)-1-hexanoicanilide ([F-18]-TFAHA). The selectivity of these radiotracer substrates to HDAC class IIa enzymes was assessed in vitro, in a panel of recombinant HDACs, and in vivo using PET/CT imaging in rats. [F-18] TFAHA showed significantly higher selectivity for HDAC class IIa enzymes, as compared to [F-18] DFAHA and previously reported [F-18] FAHA. PET imaging with [F-18] TFAHA can be used to visualize and quantify spatial distribution and magnitude of HDAC class IIa expression-activity in different organs and tissues in vivo. Furthermore, PET imaging with [F-18] TFAHA may advance the understanding of HDACs class IIa mediated epigenetic regulation of normal and pathophysiological processes, and facilitate the development of novel HDAC class IIa-specific inhibitors for therapy of different diseases.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Entinostat: A novel class I isoform selective histone deacetylase inhibitor (HDACi) with unique pharmacological properties
    Ordentlich, Peter
    Lee, Gloria
    Kunkel, Lori
    Sausville, Edward
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [32] Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease
    Buerli, Roland W.
    Luckhurst, Christopher A.
    Aziz, Omar
    Matthews, Kim L.
    Yates, Dawn
    Lyons, Kathy. A.
    Beconi, Maria
    McAllister, George
    Breccia, Perla
    Stott, Andrew J.
    Penrose, Stephen D.
    Wall, Michael
    Lamers, Marieke
    Leonard, Philip
    Mueller, Ilka
    Richardson, Christine M.
    Jarvis, Rebecca
    Stones, Liz
    Hughes, Samantha
    Wishart, Grant
    Haughan, Alan F.
    O'Connell, Catherine
    Mead, Tania
    McNeil, Hannah
    Vann, Julie
    Mangette, John
    Maillard, Michel
    Beaumont, Vahri
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (24) : 9934 - 9954
  • [33] Identifying Novel Radiotracers for PET Imaging of the Brain: Application of LC-MS/MS to Tracer Identification
    Barth, Vanessa
    Need, Anne
    ACS CHEMICAL NEUROSCIENCE, 2014, 5 (12): : 1148 - 1153
  • [34] Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy
    Turkman, Nashaat
    Liu, Daxing
    Pirola, Isabella
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
  • [35] Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs
    Liao, Qili
    Yang, Jie
    Ge, Shengfang
    Chai, Peiwei
    Fan, Jiayan
    Jia, Renbing
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2023, 13 (02) : 127 - 141
  • [36] Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation
    Park, JH
    Jung, Y
    Kim, TY
    Kim, SG
    Jong, HS
    Lee, JW
    Kim, DK
    Lee, JS
    Kim, NK
    Kim, TY
    Bang, YJ
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5271 - 5281
  • [37] Labeling of Tubastatin A with Carbon-11 in the hydroxamic acid carbonyl position for PET imaging of histone deacetylase 6 in brain
    Lu, Shuiyu
    Zhang, Yi
    Kalin, Jay H.
    Gai, Lisheng
    Kosikowzki, Alan P.
    Pike, Victor W.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 : S115 - S116
  • [38] Syntheses and Discovery of a Novel Class of Cinnamic Hydroxamates as Histone Deacetylase Inhibitors by Multimodality Molecular Imaging in Living Subjects
    Chan, C. T.
    Qi, J.
    Smith, W.
    Paranol, R.
    Mazitschek, R.
    West, N.
    Reeves, R.
    Chiosis, G.
    Schreiber, S. L.
    Bradner, J. E.
    Paulmurugan, R.
    Gambhir, S. S.
    CANCER RESEARCH, 2014, 74 (24) : 7475 - 7486
  • [39] Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment
    Elmezayen, Ammar D.
    Kemal, Yelekci
    COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2021, 92
  • [40] Preliminary PET/MR Imaging of Class I Histone Deacetylase Expression and Grey Matter Volume Loss in Huntington's Disease
    Price, Julie
    Sidwell, Amanda
    Hooker, Jacob
    Wang, Changning
    Rosas, H. Diana
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S454 - S454